One limitation of this approach is that high doses of EPO are associated with an increased risk of thrombosis in clinical settings (Bohlius et al., 2006; Corwin et al., 2007; van der Meer and van Veldhuisen, 2011). The gene discussed is EPO; the disease is Venous thrombosis.